This 4-hour course is designed for medical providers practicing addiction medicine who interact with treatment courts and the justice system. Clinicians will explore the complexities of treating justice-involved individuals and apply practical strategies through case-based learning to enhance collaboration, advocate for evidence-based care, and improve coordination with community resources.

This 1.5-hour course explores how a successful partnership was formed between addiction medicine providers and a drug treatment court. Presenters will explain how the collaboration began, how it is funded, and how it has been maintained.

This 4-hour course is designed for medical providers practicing addiction medicine who interact with treatment courts and the justice system. Clinicians will explore the complexities of treating justice-involved individuals and apply practical strategies through case-based learning to enhance collaboration, advocate for evidence-based care, and improve coordination with community resources.

This one-hour, journal article-based activity examines associations between social-environmental vulnerability (SEV), healthcare service presence, and opioid overdose rate acceleration across rural and urban communities in the United States. Learners will explore how vulnerability and geographic context are associated with differences in overdose trends and examine the relationship between the presence of opioid treatment programs (OTPs) and primary care providers (PCPs) services and overdose rate acceleration. The article also considers how healthcare service presence in high-vulnerability communities may inform strategies to address geographic and social disparities in opioid overdose outcomes.

This one-hour, journal article-based activity examines the efficacy and safety of methylphenidate (MPH) for the treatment of cocaine use disorder (CUD). Learners will explore findings from a systematic review and meta-analysis evaluating the effects of MPH on cocaine craving and use, including differences in outcomes among individuals with and without co-occurring attention-deficit/hyperactivity disorder (ADHD). The article also examines factors that may influence treatment outcomes, considerations related to the safety of MPH, and limitations in the current evidence base to inform future research and clinical practice.